Solventum Corporation (SOLV) Stock Analysis
Range Bound setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $77.07 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5.
Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales; wound therapy, sterilization, IV management), Dental Solutions (16.2%; brackets, aligners, cements), and Health Information Systems (16.3%; physician... Read more
Sell if holding. Analyst target reached at $77.07 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.6/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Solventum Corporation
Latest news
- NEWS SOLV vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance — Yahoo Finance neutral
- NEWS Solventum (SOLV) Projected to Post Earnings on Tuesday - MarketBeat — MarketBeat neutral
- NEWS Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- NEWS Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations - StockStory — StockStory positive
- NEWS Solventum gains after activist Trian sends letter urging changes (update) (SOLV:NYSE) - Seeking Alpha — Seeking Alpha positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-03-24Item 5.02MEDIUMChief Accounting Officer Mary Wilcox notified Solventum on March 20, 2026 of her intent to retire following appointment of a successor. No successor named at time of filing; no disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -3.0% YoY. Growth thesis broken unless recovery story develops.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $77.07 — A.R:R is negative (-1.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $71.75. Score 4.6/10, moderate confidence.
Take-profit target: $81.75 (+6.0% upside). Prior stop was $71.75. Stop-loss: $71.75.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5; Weak overall score: 4.6/10.
Solventum Corporation trades at a P/E of 9.7 (forward 11.2). TrendMatrix value score: 6.6/10. Verdict: Sell.
22 analysts cover SOLV with a consensus score of 3.7/5. Average price target: $82.
What does Solventum Corporation do?Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales;...
Solventum is a global healthcare company spun off from 3M in 2024, with three segments: MedSurg (57.9% of 2025 sales; wound therapy, sterilization, IV management), Dental Solutions (16.2%; brackets, aligners, cements), and Health Information Systems (16.3%; physician documentation, coding, revenue cycle software). Products are sold to hospitals, clinics and healthcare systems in 90+ countries; the company carries approximately $5B of debt from the spin-off.